This report was first published by Endpoints News. To see the original version, click here
With its fourth biotech acquisition of the year, Eli Lilly is further bolstering its gene therapy portfolio as other large drugmakers reassess their work in the complex, commercially-strained field.
The Indianapolis-based drug giant plans to acquire Adverum Biotechnologies and its Phase 3 candidate ixo-vec in a milestone-heavy deal, Lilly said Friday morning.
您已阅读15%（450字），剩余85%（2607字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。